Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol for Syncope With Sympathoadrenal Imbalance in Children
NCT00093860Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of propranolol in Neurocardiogenic syncope (NCS) (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Prevention of tilt-induced syncope or significant hypotension/bradycardia. Started Oct 2004; status: completed.
02
Drugs
propranolol
03
Conditions
Neurocardiogenic syncope (NCS)
Beyond the preview
Go deeper on NCT00093860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093860.